{"name":"Cellectar Biosciences, Inc.","slug":"cellectar-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":11498761,"netIncome":-21791037,"cash":13196033,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Iopofosine I 131 fractionated dose","genericName":"Iopofosine I 131 fractionated dose","slug":"iopofosine-i-131-fractionated-dose","indication":"Other","status":"phase_2"},{"name":"CLR 125","genericName":"CLR 125","slug":"clr-125","indication":"Other","status":"phase_1"},{"name":"Iopofosine I 131 multiple dose","genericName":"Iopofosine I 131 multiple dose","slug":"iopofosine-i-131-multiple-dose","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Iopofosine I 131 single dose","genericName":"Iopofosine I 131 single dose","slug":"iopofosine-i-131-single-dose","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_2"}]}],"pipeline":[{"name":"Iopofosine I 131 fractionated dose","genericName":"Iopofosine I 131 fractionated dose","slug":"iopofosine-i-131-fractionated-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iopofosine I 131 single dose","genericName":"Iopofosine I 131 single dose","slug":"iopofosine-i-131-single-dose","phase":"phase_2","mechanism":"Iopofosine I 131 is a phospholipid-drug conjugate that selectively targets and accumulates in cancer cells, allowing for targeted radiation therapy.","indications":["Relapsed or refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"CLR 125","genericName":"CLR 125","slug":"clr-125","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iopofosine I 131 multiple dose","genericName":"Iopofosine I 131 multiple dose","slug":"iopofosine-i-131-multiple-dose","phase":"phase_2","mechanism":"Iopofosine I 131 is a radioiodinated phospholipid ether analog that selectively accumulates in cancer cells and delivers targeted radiation therapy.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE05ajdrRmVrdERkQjVIOEFVWWJDdHlNdExILWNaXzFsSk1ZTmFZUTBURHRqT3B5eTZqbzE2bzJxNlhPaHh1dUM3cUoycUdSSGpsa0VVNmJ2N0gtV19iR0ROZ0tCV2pabWVkbkFIX1d3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Cellectar Biosciences Inc (CLRB) - Stock Titan","headline":"If You Invested $1,000 in Cellectar Biosciences Inc (CLRB)","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPQ1JWYlkyVWRnX0JNOHQ4eTBIaVRFLTBaZEFPQ1J4b3Jld28ySGdqNk0zLUNkQnAyREZzNVVmd3d2eElQWkFQbHpvV2tqMG9CaXREZzl6NFV6TXhXSnNMZ29YTUo4dFJra2ktdk1uRnBuUFZGTVVDeDBObE9fWTJWN3pwNUp4bXR4Q3I1VzYyTG03bDJwT0FQZWdIUjU1dUZIcTBINnVtbHU5c3NNclBXX1dNbEZwdUNDN1YyTTc4YmdFR05pSmRtdlEyTUhUMlptZm9j?oc=5","date":"2026-01-12","type":"regulatory","source":"Benzinga","summary":"Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxNOHJCbmRISWktdFEySzE2WEFRX0ZKT3J0OXlzVW1fR2l1bWJteXV1ZUdtbUdjQXFzTnpFWjdKSV90QjJmUWp3OWtCaUVza2NSRktaT2V6WVdtTVROLWZLdUh4MHpoQklDZHBNRVh6Q3dLQTlhNjVna3BwMVhjSnp6cUhPMTlfTlZRSHhIRmE5TkhDVXFXYkREVWlXWmtJVnJfcHBuZ0tGZmZjMlpqVXdIZEI5RHhSWlBRajlVOXN2Y01ZUmVjOHYtRVBXQVRQNmc0eUdDNENHZFRLZUotSkJSUjA4Um9yeGh1amUxTTFOQTNaUDVjYmxON1AzdnVFeVRuRFB6QUJfRmFyZHYtZ0lCS3VVcERyaG5qenFGOGlIaDMwQzlOQS1pS1FjcTZGR1kwOVQwMklYaFFRdG4xV1E?oc=5","date":"2026-01-09","type":"pipeline","source":"GlobeNewswire","summary":"Cellectar Biosciences to Highlight Strategic Initiatives - GlobeNewswire","headline":"Cellectar Biosciences to Highlight Strategic Initiatives","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNRV9IUWEwdmI4VklzQmJQeURkSmEyUmhncG1KbGdnNHJldXRuQzlocGNFWEEwUjBVSFNCZmRPYmdDb2V0a0VOY3AyT0I3RXNUYl9sX2xaOVZxRDNUN2wtZ2NXOGZjUUxMSnBUUU4zZEFYZGVJZ1VXZWVPOGswTm5Iei1VRDd5RjBEay1wdEtzcWRqWF9SNkp1X00xRTZNbXlaVkk3dDJ4SlFjRUptcnhSSnlPWEhZeWJSdWtYX3dZYXJaSVM4NjdGMFFDYzlNRzBoYWFrX3A4Yng0SGxlamFCZ0tXaTFrOHYxTDdneTh3Y3AyVFc2QkJBZG5zSjZ1U01ZZ0ZnMGgxUWdxLXVvQWNNZzBLM3hOODNXSU51TTZ2ekE?oc=5","date":"2025-11-06","type":"earnings","source":"GlobeNewswire","summary":"Cellectar Biosciences to Report Third Quarter Financial - GlobeNewswire","headline":"Cellectar Biosciences to Report Third Quarter Financial","sentiment":"neutral"},{"date":"2025-10-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - PR Newswire","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUUVIV2FCOEN3RkhDdmNlQjVMLXIzcjhSeTYtVUZhTzlPelY0Ykc3WTJuWHRfMnlhd1AzWGN1ZFNRdUFIeW9GSVc3X1lZSlpLV2FKRVVZY2YtR2llYTlfYl92MldjYlp3VHUxMFZza0xMYTFqSHBKMXhyaGtXbl9tU3NpZFlmQlA5bk1KanBwdHF2ZTRMYzcw?oc=5","date":"2025-04-30","type":"pipeline","source":"Fierce Biotech","summary":"Cellectar is seeking strategic alternatives, sinking stock - Fierce Biotech","headline":"Cellectar is seeking strategic alternatives, sinking stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQU1hWZldGLUNjek9jTF9rb0o2QTctWW5xNk1Xc1hRM2pUc05MV2kwN0JJTGtGSnBSSm04MUFPaFptcW0tN0FHb3BFRjJQNnhfdkFWQmJMOHpBTGUydk9KdFBWN3RCdnczSjNXQ1VqbnlRZVFQZ0RpbzlyU2p6WkFXdW9JTUx0dUtTZFE1ZHdHdlFiT3dLMDBBY3lzYS1ZOXgwdXFnSzZmNlR6aElzOXI0?oc=5","date":"2025-02-02","type":"pipeline","source":"Investing.com","summary":"Cellectar faces Nasdaq delisting over share price rule - Investing.com","headline":"Cellectar faces Nasdaq delisting over share price rule","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_1":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11498761,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-21791037,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":13196033,"cashHistory":[],"totalAssets":14978321,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}